Search

A population PK-PD model for effects of Sipoglitazar on FPG and HbA1c in patients with type II diabetes

Therapeutic area :

Stringer F., DeJongh J., Scott G. and Danhof M., A population PK-PD model for effects of Sipoglitazar on FPG and HbA1c in patients with type II diabetes. PAGE.(2013) [Link to publication]

Our expertise

Lung Diseases General modelling Paediatrics Cardiovascular Diabetes CNS Blood disorders Methods Anti-infectives and immunology Pain Biologicals Endocrinology/Sexual health Peripheral Nervous System Anesthesiology Gastrointestinal Diseases Oncology Safety pharmacology